Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Depreciation & Amortization (CF) (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $599000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 55.1% to $599000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, down 34.9% year-over-year, with the annual reading at $3.6 million for FY2025, 34.9% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $599000.0 at Relay Therapeutics, down from $748000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $1.4 million in Q1 2024, with the low at $599000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $1.1 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 39.54% in 2023, then tumbled 55.1% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $1.0 million in 2021, then rose by 12.77% to $1.2 million in 2022, then increased by 17.92% to $1.4 million in 2023, then fell by 2.98% to $1.3 million in 2024, then crashed by 55.1% to $599000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $599000.0, $748000.0, and $1.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.